Ken Garber. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Angiogenesis Inhibitors/pharmacologyAnimalsAntineoplastic Agents/pharmacologyBiomedical ResearchDrug DesignDrug Industry/organization & administrationDrug Industry/trendsDrugs, Investigational/pharmacologyEndothelial Growth Factors/antagonists & inhibitorsErlotinib HydrochlorideGermanyHumansIndoles/pharmacologyIntercellular Signaling Peptides and ProteinsLymphokines/antagonists & inhibitorsNeoplasms/drug therapyNeoplasms/metabolismPyrroles/pharmacologyQuinazolines/pharmacologySignal Transduction/drug effectsUnited StatesVascular Endothelial Growth Factor AVascular Endothelial Growth Factors
Substances： See more » Angiogenesis InhibitorsAntineoplastic AgentsDrugs, InvestigationalEndothelial Growth FactorsIndolesIntercellular Signaling Peptides and ProteinsLymphokinesPyrrolesQuinazolinesVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsSemaxinibErlotinib Hydrochloride
Year: 2003 PMID： 12865446 DOI： 10.1093/jnci/95.14.1036
Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506